Preferential Binding to Elk-1 by SLE-Associated Risk Allele Upregulates Expression

English version České info

Immunoregulatory cytokine interleukin-10 (IL-10) is elevated in sera from patients with systemic lupus erythematosus (SLE) correlating with disease activity. The established association of IL10 with SLE and other autoimmune diseases led us to fine map causal variant(s) and to explore underlying mechanisms. We assessed 19 tag SNPs, covering the IL10 gene cluster including IL19, IL20 and IL24, for association with SLE in 15,533 case and control subjects from four ancestries. The previously reported IL10 variant, rs3024505 located at 1 kb downstream of IL10, exhibited the strongest association signal and was confirmed for association with SLE in European American (EA) (P = 2.7×10⁻⁸, OR = 1.30), but not in non-EA ancestries. SNP imputation conducted in EA dataset identified three additional SLE-associated SNPs tagged by rs3024505 (rs3122605, rs3024493 and rs3024495 located at 9.2 kb upstream, intron 3 and 4 of IL10, respectively), and SLE-risk alleles of these SNPs were dose-dependently associated with elevated levels of IL10 mRNA in PBMCs and circulating IL-10 protein in SLE patients and controls. Using nuclear extracts of peripheral blood cells from SLE patients for electrophoretic mobility shift assays, we identified specific binding of transcription factor Elk-1 to oligodeoxynucleotides containing the risk (G) allele of rs3122605, suggesting rs3122605 as the most likely causal variant regulating IL10 expression. Elk-1 is known to be activated by phosphorylation and nuclear localization to induce transcription. Of interest, phosphorylated Elk-1 (p-Elk-1) detected only in nuclear extracts of SLE PBMCs appeared to increase with disease activity. Co-expression levels of p-Elk-1 and IL-10 were elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best downregulated by ERK inhibitor. Taken together, our data suggest that preferential binding of activated Elk-1 to the IL10 rs3122605-G allele upregulates IL10 expression and confers increased risk for SLE in European Americans.

Vyšlo v časopise: Preferential Binding to Elk-1 by SLE-Associated Risk Allele Upregulates Expression. PLoS Genet 9(10): e32767. doi:10.1371/journal.pgen.1003870
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003870

Souhrn

Zdroje

1. JohannesonB, LimaG, von SalomeJ, Alarcon-SegoviaD, Alarcon-RiquelmeME (2002) A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet 71: 1060–1071.

2. WuH, BoackleSA, HanvivadhanakulP, UlgiatiD, GrossmanJM, et al. (2007) Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci U S A 104: 3961–3966.

3. GatevaV, SandlingJK, HomG, TaylorKE, ChungSA, et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41: 1228–1233.

4. FrankeA, McGovernDP, BarrettJC, WangK, Radford-SmithGL, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118–1125.

5. FrankeA, BalschunT, KarlsenTH, SventoraityteJ, NikolausS, et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40: 1319–1323.

6. AndersonCA, BoucherG, LeesCW, FrankeA, D'AmatoM, et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246–252.

7. BarrettJC, ClaytonDG, ConcannonP, AkolkarB, CooperJD, et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41: 703–707.

8. PlagnolV, HowsonJM, SmythDJ, WalkerN, HaflerJP, et al. (2011) Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 7: e1002216.

9. RemmersEF, CosanF, KirinoY, OmbrelloMJ, AbaciN, et al. (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 42: 698–702.

10. MizukiN, MeguroA, OtaM, OhnoS, ShiotaT, et al. (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 42: 703–706.

11. HofmannSR, Rosen-WolffA, TsokosGC, HedrichCM (2012) Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 143: 116–127.

12. PestkaS, KrauseCD, SarkarD, WalterMR, ShiY, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929–979.

13. ParkYB, LeeSK, KimDS, LeeJ, LeeCH, et al. (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16: 283–288.

14. HoussiauFA, LefebvreC, Vanden BergheM, LambertM, DevogelaerJP, et al. (1995) Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393–395.

15. LlorenteL, Richaud-PatinY, Garcia-PadillaC, ClaretE, Jakez-OcampoJ, et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790–1800.

16. LlorenteL, Richaud-PatinY, CoudercJ, Alarcon-SegoviaD, Ruiz-SotoR, et al. (1997) Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 40: 1429–1435.

17. GrondalG, KristjansdottirH, GunnlaugsdottirB, ArnasonA, LundbergI, et al. (1999) Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 42: 1649–1654.

18. BeebeAM, CuaDJ, de Waal MalefytR (2002) The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 13: 403–412.

19. OkamotoA, FujioK, OkamuraT, YamamotoK (2011) Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011: 463412.

20. GladmanDD, UrowitzMB, KagalA, HallettD (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27: 377–379.

21. YeeCS, FarewellVT, IsenbergDA, GriffithsB, TehLS, et al. (2011) The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 50: 982–988.

22. LavaurJ, BernardF, TrifilieffP, PascoliV, KappesV, et al. (2007) A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J Neurosci 27: 14448–14458.

23. BanchereauJ, PascualV (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383–392.

24. van der LindenMW, WestendorpRG, SturkA, BergmanW, HuizingaTW (2000) High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med 48: 327–334.

25. GrondalG, KristjansdottirH, GunnlaugsdottirB, ArnasonA, LundbergI, et al. (1999) Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 42: 1649–1654.

26. EskdaleJ, WordsworthP, BowmanS, FieldM, GallagherG (1997) Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 49: 635–639.

27. MehrianR, QuismorioFPJr, StrassmannG, StimmlerMM, HorwitzDA, et al. (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41: 596–602.

28. D'AlfonsoS, RampiM, BocchioD, ColomboG, Scorza-SmeraldiR, et al. (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43: 120–128.

29. MokCC, LanchburyJS, ChanDW, LauCS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41: 1090–1095.

30. RoodMJ, KeijsersV, van der LindenMW, TongTQ, BorggreveSE, et al. (1999) Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis 58: 85–89.

31. GibsonAW, EdbergJC, WuJ, WestendorpRG, HuizingaTW, et al. (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166: 3915–3922.

32. TrynkaG, SandorC, HanB, XuH, StrangerBE, et al. (2013) Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 45: 124–130.

33. SharrocksAD (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827–837.

34. RaoVN, ReddyES (1994) elk-1 proteins interact with MAP kinases. Oncogene 9: 1855–1860.

35. LiW, MarshallC, MeiL, DzubowL, SchmultsC, et al. (2005) Srcasm modulates EGF and Src-kinase signaling in keratinocytes. J Biol Chem 280: 6036–6046.

36. SharmaA, CallahanLM, SulJY, KimTK, BarrettL, et al. (2010) A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases. PLoS One 5: e9002.

37. MorrisJF, SulJY, KimMS, Klein-SzantoAJ, SchochetT, et al. (2013) Elk-1 phosphorylated at threonine-417 is present in diverse cancers and correlates with differentiation grade of colonic adenocarcinoma. Hum Pathol 44: 766–776.

38. GrammerAC, FischerR, LeeO, ZhangX, LipskyPE (2004) Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 6: 28–38.

39. WongCK, WongPT, TamLS, LiEK, ChenDP, et al. (2009) Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 29: 738–746.

40. BesnardA, Galan-RodriguezB, VanhoutteP, CabocheJ (2011) Elk-1 a transcription factor with multiple facets in the brain. Front Neurosci 5: 35.

41. OdrowazZ, SharrocksAD (2012) ELK1 uses different DNA binding modes to regulate functionally distinct classes of target genes. PLoS Genet 8: e1002694.

42. LiJC, LauAS (2007) A role for mitogen-activated protein kinase and Ets-1 in the induction of interleukin-10 transcription by human immunodeficiency virus-1 Tat. Immunology 121: 337–348.

43. LeeCG, KwonHK, SahooA, HwangW, SoJS, et al. (2012) Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cells. J Immunol 188: 2244–2253.

44. HanJW, ZhengHF, CuiY, SunLD, YeDQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234–1237.

45. YangW, ShenN, YeDQ, LiuQ, ZhangY, et al. (2010) Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. PLoS Genet 6: e1000841.

46. EyquemS, CheminK, FasseuM, ChopinM, SigauxF, et al. (2004) The development of early and mature B cells is impaired in mice deficient for the Ets-1 transcription factor. Eur J Immunol 34: 3187–3196.

47. WangD, JohnSA, ClementsJL, PercyDH, BartonKP, et al. (2005) Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int Immunol 17: 1179–1191.

48. GrenninglohR, KangBY, HoIC (2005) Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J Exp Med 201: 615–626.

49. MoisanJ, GrenninglohR, BettelliE, OukkaM, HoIC (2007) Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 204: 2825–2835.

50. LlorenteL, Richaud-PatinY, WijdenesJ, Alcocer-VarelaJ, MaillotMC, et al. (1993) Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 4: 421–427.

51. LlorenteL, Richaud-PatinY, FiorR, Alcocer-VarelaJ, WijdenesJ, et al. (1994) In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37: 1647–1655.

52. al-JanadiM, al-DalaanA, al-BallaS, al-HumaidiM, RaziuddinS (1996) Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 16: 198–207.

53. CsiszarA, NagyG, GergelyP, PozsonyiT, PocsikE (2000) Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 122: 464–470.

54. NakanoS, MorimotoS, SuzukiJ, NozawaK, AmanoH, et al. (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47: 145–149.

55. SchickelJN, PasqualiJL, SoleyA, KnappAM, DecossasM, et al. (2012) Carabin deficiency in B cells increases BCR-TLR9 costimulation-induced autoimmunity. EMBO Mol Med 4: 1261–1275.

56. RoussetF, GarciaE, DefranceT, PeronneC, VezzioN, et al. (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89: 1890–1893.

57. LlorenteL, Richaud-PatinY (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20: 287–289.

58. YangM, RuiK, WangS, LuL (2013) Regulatory B cells in autoimmune diseases. Cell Mol Immunol 10: 122–132.

59. BlairPA, Chavez-RuedaKA, EvansJG, ShlomchikMJ, EddaoudiA, et al. (2009) Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 182: 3492–3502.

60. HaasKM, WatanabeR, MatsushitaT, NakashimaH, IshiuraN, et al. (2010) Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 184: 4789–4800.

61. WatanabeR, IshiuraN, NakashimaH, KuwanoY, OkochiH, et al. (2010) Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 184: 4801–4809.

62. ScapiniP, LamagnaC, HuY, LeeK, TangQ, et al. (2011) B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proc Natl Acad Sci U S A 108: E823–832.

63. TeichmannLL, KashgarianM, WeaverCT, RoersA, MullerW, et al. (2012) B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL.Fas(lpr) mice. J Immunol 188: 678–685.

64. BlairPA, NorenaLY, Flores-BorjaF, RawlingsDJ, IsenbergDA, et al. (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32: 129–140.

65. IwataY, MatsushitaT, HorikawaM, DililloDJ, YanabaK, et al. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117: 530–541.

66. OkadaY, ShimaneK, KochiY, TahiraT, SuzukiA, et al. (2012) A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet 8: e1002455.

67. LeeHS, KimT, BangSY, NaYJ, KimI, et al. (2013) Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. Ann Rheum Dis [Epub ahead of print].

68. YangW, TangH, ZhangY, TangX, ZhangJ, et al. (2013) Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet 92: 41–51.

69. FairfaxBP, MakinoS, RadhakrishnanJ, PlantK, LeslieS, et al. (2012) Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 44: 502–510.

70. GrundbergE, SmallKS, HedmanAK, NicaAC, BuilA, et al. (2012) Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 44: 1084–1089.

71. DimasAS, DeutschS, StrangerBE, MontgomerySB, BorelC, et al. (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325: 1246–1250.

72. StrangerBE, MontgomerySB, DimasAS, PartsL, StegleO, et al. (2012) Patterns of cis regulatory variation in diverse human populations. PLoS Genet 8: e1002639.

73. SzkaradkiewiczA, MarciniakR, Chudzicka-StrugalaI, WasilewskaA, DrewsM, et al. (2009) Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 57: 291–294.

74. WangAH, LamWJ, HanDY, DingY, HuR, et al. (2011) The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol 72: 431–435.

75. KucharzikT, StollR, LugeringN, DomschkeW (1995) Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100: 452–456.

76. KuhnR, LohlerJ, RennickD, RajewskyK, MullerW (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.

77. SpencerSD, Di MarcoF, HooleyJ, Pitts-MeekS, BauerM, et al. (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187: 571–578.

78. GlockerEO, KotlarzD, BoztugK, GertzEM, SchafferAA, et al. (2009) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033–2045.

79. ScofieldRH, KaufmanKM (2012) Mapping susceptibility gene in systemic lupus erythematosus. Methods Mol Biol 900: 11–24.

80. HochbergMC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.

81. PriceAL, PattersonNJ, PlengeRM, WeinblattME, ShadickNA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.

82. HoggartCJ, ParraEJ, ShriverMD, BonillaC, KittlesRA, et al. (2003) Control of confounding of genetic associations in stratified populations. Am J Hum Genet 72: 1492–1504.

83. HoggartCJ, ShriverMD, KittlesRA, ClaytonDG, McKeiguePM (2004) Design and analysis of admixture mapping studies. Am J Hum Genet 74: 965–978.

84. McKeiguePM (2005) Prospects for admixture mapping of complex traits. Am J Hum Genet 76: 1–7.

85. LessardCJ, AdriantoI, KellyJA, KaufmanKM, GrundahlKM, et al. (2011) Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet 88: 83–91.

86. HowieBN, DonnellyP, MarchiniJ (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5: e1000529.

87. GladmanDD, IbanezD, UrowitzMB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288–291.

88. TanW, WuH, ZhaoJ, DerberLA, LeeDM, et al. (2010) A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis Rheum 62: 2864–2875.

89. PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

90. BarrettJC, FryB, MallerJ, DalyMJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.